Aclarion (ACON) Projected to Post Quarterly Earnings on Wednesday

Aclarion (NASDAQ:ACON) will likely be announcing its Q4 2025 results before the market opens on Wednesday, February 25th. Analysts expect the company to announce earnings of ($3.60) per share and revenue of $0.02 million for the quarter. Investors can find conference call details on the company’s upcoming Q4 2025 earning report page for the latest details on the call scheduled for Friday, March 20, 2026 at 10:30 AM ET.

Aclarion Stock Down 0.8%

NASDAQ ACON traded down $0.02 during trading hours on Friday, reaching $2.54. The company’s stock had a trading volume of 31,202 shares, compared to its average volume of 110,617. Aclarion has a 1 year low of $2.34 and a 1 year high of $229.50. The firm’s 50-day moving average price is $4.20 and its 200-day moving average price is $6.23. The company has a market capitalization of $2.16 million, a price-to-earnings ratio of -0.17 and a beta of 1.44.

Analyst Upgrades and Downgrades

Several brokerages have commented on ACON. Wall Street Zen raised Aclarion from a “sell” rating to a “hold” rating in a research report on Sunday. Weiss Ratings reissued a “sell (e+)” rating on shares of Aclarion in a research note on Wednesday, January 21st. One investment analyst has rated the stock with a Sell rating, According to MarketBeat.com, the stock has a consensus rating of “Sell”.

Aclarion Company Profile

Aclarion, Inc, a healthcare technology company, leverages for Magnetic Resonance Spectroscopy (MRS) in the United States. It develops NOCISCAN Post-Processor suite of software applications comprising NOCICALC that receives the raw un-processed NOCISCAN MRS exam data and post-processes that raw data into final spectra and performs various degenerative pain biomarker; and NOCIGRAM, a clinical decision support software. The company was formerly known as Nocimed, Inc and changed its name to Aclarion, Inc in December 2021.